Australia markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6000+0.1400 (+9.59%)
At close: 04:00PM EST
1.5800 -0.02 (-1.25%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.4600
Open1.4700
Bid0.0000 x 3200
Ask0.0000 x 900
Day's range1.4700 - 1.6200
52-week range1.0000 - 6.7400
Volume897,744
Avg. volume1,777,285
Market cap139.962M
Beta (5Y monthly)0.78
PE ratio (TTM)N/A
EPS (TTM)-1.5300
Earnings date04 Mar 2024 - 08 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.90
  • GlobeNewswire

    Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

    – Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced skin inflammation model – SAN CARLOS, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory an

  • GlobeNewswire

    Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

    – Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the publicatio

  • Zacks

    Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

    Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.